801748--4/14/2008--HEMACARE_CORP

related topics

{stock, price, share}

{regulation, government, change}

{acquisition, growth, future}

{product, liability, claim}

{cost, operation, labor}

{cost, regulation, environmental}

{operation, natural, condition}

{personnel, key, retain}

{control, financial, internal}

{stock, price, operating}

{gas, price, oil}

{customer, product, revenue}

{product, market, service}

{debt, indebtedness, cash}

{provision, law, control}

{property, intellectual, protect}

Company has reported losses for four consecutive quarters and may not return to profitability Discontinuation of the operations of the Company's Florida-based research subsidiary may hinder the Company's ability to generate profits Steady or declining market prices and increased costs could reduce profitability Changes in demand for blood products could affect profitability Declining blood donations could affect profitability Competition may cause a loss of customers and an inability to pass on increases in costs thereby impacting profitability The Company is in default on notes to former owners of HemaBio which could result in acceleration of note obligations which the Company may not have sufficient resources to satisfy. Operations depend on services of qualified professionals and competition for their services is strong Industry regulations and standards could increase operating costs or result in closure of operations Decrease in reimbursement rates may affect profitability Not-for-profit status gives advantages to competitors Potential inability to meet future capital needs could impact ability to operate Reliance on relatively few vendors for significant supplies and services could affect the Company's ability to operate Potential adverse effect from changes in the healthcare industry, including consolidations, could affect access to customers Targeted partner blood drives involve higher collection costs Future technological developments or alternative treatments could jeopardize business Limited access to insurance could affect ability to defend against possible claims Ability to attract, retain and motivate management and other skilled employees Product safety and product liability could provide exposure to claims and litigation Environmental risks could cause the Company to incur substantial costs to maintain compliance Business interruption due to terrorism and increased security measures in response to terrorism could adversely impact profitability Business interruption due to earthquakes could adversely impact profitability Evaluation and consideration of strategic alternatives, and other significant projects, may distract management from reacting appropriately to business challenges and lead to reduced profitability Strategy to acquire companies may result in unsuitable acquisitions or failure to successfully integrate acquired companies, which could lead to reduced profitability Articles of Incorporation and Rights Plan could delay or prevent an acquisition or sale of HemaCare Quarterly revenue and operating results may fluctuate in future periods, and the Company may fail to meet investor expectations Stocks traded on the OTC Bulletin Board are subject to greater market risks than those of exchange-traded stocks since they are less liquid Stock price could be volatile Future sales of equity securities could dilute the Company's common stock Lack of dividend payments could impact the price of the Company's common stock Evaluation of internal control and remediation of potential problems will be costly and time consuming and could expose weaknesses in financial reporting

Full 10-K form ▸

801748--4/14/2008--HEMACARE_CORP_/CA/